The AIM Study: Assessing the Impact of Margin Reduction (AIM)
Sponsor: Varian, a Siemens Healthineers Company
A observational or N/A phase clinical study on Prostate Cancer, this trial is completed. The trial is conducted by Varian, a Siemens Healthineers Company and has accumulated 8 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2022 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Jan 2022 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Varian, a Siemens Healthineers Company
For direct contact, visit the study record on ClinicalTrials.gov .